Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
H1 histone family, member 0 (H1F0) is a member of the H1 histone family of nuclear proteins. It has been shown that, H1F0 is expressed by oocytes from the GV stage to the 2-cell embryo stage in mice and human. Some reports have underlined that H1F0’s coding regions encoded 195 amino acids. The yak H1F0 protein had high similarities with other mammalian species. Hui-Ran Niu et al. has shown that H1F0 is thought to be the predominant H1 histone associated with chromatin during oocyte growth, maturation and early embryogenesis. Keiko Ichihara-Tanaka et al. shows that the accumulation of H1f0 is related to the development of brain tissue. For example, the accumulation of H1f0 coincides with the terminal differentiation of the brain cortex. Furthermore, total expression level of H1f0 gradually decreased from E12.5 to adulthood in brain tissues.
Some researches proved that H1F0 silencing occurs specifically in cancer stem cells (CSCs). Histone H1F0 accumulation has been associated with terminal differentiation in normal cells, while it downgrades in neoplastic cells and different cancer types. At a molecular level, H1F0 showed a mutually exclusive relationship with SSEA1, which is stem cell surface marker Stage Specific Embryonic Antigen 1. At protein level, down-regulation of H1F0 could either decrease the total H1:core histone ratio or instead H1F0 loss could be compensated by an increase of other H1 subtypes.
According to related research, the knockdown of H1F0 in human embryonic stem cells (ESCs) in vitro impaired the induction of genes associated with differentiation (HNF4, Sox17 and FoxA2), suggesting a potential role of H1F0 in regulating specific genes during human ESC differentiation. In addition, H1F0 was enriched at nucleolar-associated domains, rDNA and certain repeats In T47D. Moreover, the analysis of transcriptional data showed that the genes up-regulated upon H1F0 knockdown were associated with oncogene activation and tumor-suppressor inactivation. Therefore, Torres concluded that cells lacking H1F0 undergo genome wide changes in gene expression, triggered by alterations in the nucleosome occupancy around the TSS of genes in AT-rich domains, which led to the up-regulation of genes associated with cancer-cell self-renewal ability. Mechanistically, H1F0 depletion destabilizes nucleosome DNA interactions to promote the expression of self-renewal genes. Gene expression changes following H1F0 loss were reversible and epigenetic states restricting cell proliferation potential were reestablished upon H1F0 re-expression. Moreover, deletion of CpG shore by genome editing resulted in a decrease in the H1F0 mRNA levels, this result indicates that H1F0 gene silencing in self-renewing tumor cells is, at least in part, due to the methylation of this enhancer region.
Some researches reported that H1F0 gene is a susceptibility gene associated with the taxol resistance (txr) phenotype. H1F0 binds to AR (androgen receptor) which is a transcription factor and uses AR as a major enhancer of gene expression. As a prominent txr susceptibility gene candidate, the expression of H1F0 is down-regulated by silencing AR transcription factors. What’s more, there are some transcription factors involved in H1F0 expression activation and regulation. HBP1, a high-mobility group box transcription factor, interacted specifically with the H4-box in H1F0 promoter and involved in the activation of H1F0 gene expression, providing a link between the cell cycle control machinery and cell differentiation signals. The transcription factor NF-kappaB is actively involved in the regulation of H1F0 during differentiation.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.